Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

2-anilino-4-aminoalkyleneaminopyrimidines

a technology of aminopyrimidines and aminoalkylenes, applied in the field of aminoalkyleneaminopyrimidines, can solve the problems of symptomatic heart failure, reduced cardiac output, and impaired diastolic and/or systolic function, and achieve the effect of slowing the progression of heart failure, improving myocardial contraction and relaxation performan

Inactive Publication Date: 2007-12-20
BOEHRINGER INGELHEIM INT GMBH
View PDF6 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] The present invention meets the aforementioned needs in that it has been found that certain 2-arylamino-4-(aminoalkylene)aminopyrimidines are effective for inhibiting Protein Kinase C-alpha (PKC-α) thereby improving myocardial contraction and relaxation performance and slowing the progression of heart failure.
[0030] The third major aspect of the present invention relates to methods of use. As described herein below, the PKC-α inhibitors of the present invention are important for improving myocardial contraction and relaxation performance and thereby slowing the progression of heart failure and their administration to humans is, therefore, an effective treatment for humans suffering from acute heart failure.

Problems solved by technology

While the root cause of heart failure is multifaceted, it uniformly is marked by impaired diastolic and / or systolic function and can be accompanied by chamber enlargement which ultimately manifest in symptomatic heart failure (fatigue, pulmonary edema, circulatory congestion, etc.)
Patients with acute decompensated heart failure (ADHF) are a treatment challenge to physicians and can present with volume overload and / or diminished cardiac output.
Despite the widespread use of these agents, long-term safety and benefit of these drugs have been questioned.
Therefore, there is a limited means to treat patients with various forms and stages of heart failure and there is incentive to develop novel, safe and effective treatments to prevent or treat patients with symptoms of heart failure, acute exacerbation of heart failure and chronic heart failure and other cardiovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-anilino-4-aminoalkyleneaminopyrimidines
  • 2-anilino-4-aminoalkyleneaminopyrimidines
  • 2-anilino-4-aminoalkyleneaminopyrimidines

Examples

Experimental program
Comparison scheme
Effect test

example 1

N2-(3-chlorophenyl)-N4-(3-(dimethylamino)propyl)pyrimidine-2,4-diamine (4)

[0179] Preparation of 2-(methylthio)pyrimidine-4(3H)-one (1): To a solution of sodium hydroxide (6.24 g, 156.07 mmol) in H2O (55 mL) at room temperature is added thiouridine (10 g, 78.03 mmol). The resulting mixture is stirred at room temperature for 20 min. Methyl iodide (5.45 mL, 87.40 mmol) in THF (10 mL) is added dropwise slowly and the mixture is stirred at room temperature for 18 hours. A white solid forms upon acidifying the mixture to pH 5 with glacial acetic acid. The mixture is allowed to stand at 0° C. (ice bath) for 2 hours and filtered to afford 7.4 g (67% yield) of the desired compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 2.45 (s, 3H), 6.07 (d, J=6.6 Hz, 1H), 7.85 (d, J=6.6 Hz, 1H).

[0180] Preparation of 2-(3-chlorophenylamino)pyrimidin-4(3H)-one (2): To 2-(methyl-thio)pyrimidine-4(3H)-one, 1, (4.88 g, 34.37 mmol) in diglyme (20 mL) is added 3-chloroaniline (4.3 mL, 68.74 mmol). The re...

example 2

N4-[3-(dimethylamino)-2,2-dimethylpropyl]-N2-[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine hydrochloride (7)

[0223] Preparation of 2-(3-trifluoromethylphenylamino)pyrimidin-4(3H)-one (5): To 2-(methyl-thio)pyrimidine-4(3H)-one, 1, (5 g, 35.21 mmol) in diglyme (25 mL) is added 3-trifluoromethylaniline (5.26 mL, 42.25 mmol). The resulting mixture is heated to reflux and stirred for 18 hours. A solid forms upon cooling the mixture to room temperature. The solid is washed with hexanes to afford 1.9 g (21% yield) of the desired compound. MS (ESI, pos. ion) m / z: 256 (M+1).

[0224] Preparation of 4-chloro-N-(3-trifluoromethylphenyl)pyrimidin-2-amine (6): To 2-(3-chloro-phenylamino)pyrimidin-4(3H)-one, 5, (1.9 g, 7.4 mmol) and N,N-dimethyl-aniline (2 mL) is added of phosphorus oxychloride (20 mL). The resulting mixture is heated to reflux for 15 minutes, cooled to room temperature and concentrated in vacuo. The residue is neutralized to pH 7 with 1M NaOH (aqueous). The organic layer is e...

example 3

N2-(3-chlorophenyl)-N4-(4-(dimethylamino)butyl)pyrimidine-2,4-diamine (8)

[0227] Preparation of N2-(3-chlorophenyl)-N4-(4-(dimethylamino)butyl)pyrimidine-2,4-diamine(8): To 4-chloro-N-(3-chlorophenyl)pyrimidin-2-amine (0.2 g, 0.84 mmol) in THF (4 mL) is added diisopropylethylamine (0.29 mL, 1.67 mmol) followed by 4-dimethylamino)butylamine (0.2 g, 1.67 mmol). The resulting mixture is heated to reflux for 6 hours. Another 2 equivalents of 4-dimethylamino)butylamine (0.2 g, 1.67 mmol) are added and the reaction heated at reflux for 18 hours. The reaction is cooled to room temperature and concentrated in vacuo. The residue is diluted with water (5 mL) and extracted with EtOAc (3×25 mL). The combined organic layers are dried (MgSO4) and concentrated in vacuo. This residue is purified over silica (5% MeOH in CH2Cl2 with 0.7% Et3N) to afford 7 mg (3% yield) of the desired compound. 1H NMR (CD3OD, 300 MHz): δ 1.62-1.66 (m, 4H), 2.26 (s, 6H), 2.39-2.44 (m, 2H), 3.46-3.48 (m, 2H), 5.97 (d, J...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

Description

RELATED CASES [0001] Benefit is claimed to U.S. provisional Application No. 60 / 813,875 filed Jun. 15, 2006 the contents of which are incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines which are inhibitors of Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure. BACKGROUND OF THE INVENTION [0003] Many biologically active substances, for example, hormones, neurotransmitters and peptides are known to exert functions via intracellular mediators such as, cyclic adenosine mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/505C07D239/48C07D239/50
CPCC07D239/48C07D417/12C07D403/12C07D401/12A61P13/02A61P13/12A61P25/02A61P27/02A61P29/00A61P35/00A61P3/06A61P43/00A61P7/02A61P9/00A61P9/04A61P9/06A61P9/10A61P9/12A61P3/10A61K31/4178
Inventor DJUNG, JANE FAR-JINEGOLEBIOWSKI, ADAMHUNTER, JACK A.SHRUM, GARY P.
Owner BOEHRINGER INGELHEIM INT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com